Distinguished in Pulmonary Hypertension

Dr. Christina Migliore

Intensive Care Medicine
Newark Beth Israel Medical Center
201 Lyons Ave # 16, 
Newark, NJ 
Offers Telehealth
Distinguished in Pulmonary Hypertension
Newark Beth Israel Medical Center
201 Lyons Ave # 16, 
Newark, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christina Migliore is an Intensive Care Medicine provider in Newark, New Jersey. Dr. Migliore is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Hypertension. Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Pulmonary Fibrosis, and Pneumonia.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 5 clinical trials in the study of Pulmonary Hypertension.

Specialties
Intensive Care Medicine
Licenses
Internal Medicine in NJ
Hospital Affiliations
Newark Beth Israel Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Newark Beth Israel Medical Center
201 Lyons Ave # 16, Newark, NJ 07112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

3 Total Publications

Fungemia in COVID-19 ICU patients, a single medical center experience.
Fungemia in COVID-19 ICU patients, a single medical center experience.
Journal: Journal of medical virology
Published: August 27, 2020
Similar Doctors
Roxana Sulica
Elite in Pulmonary Hypertension
Dr. Roxana Sulica
Intensive Care Medicine
Elite in Pulmonary Hypertension
Dr. Roxana Sulica
Intensive Care Medicine

NYU Langone Pulmonary Associates-Gramercy

301 E 17th St Ste 550, 
New York, NY 
 (48.6 miles away)
212-263-1260
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Roxana Sulica is an Intensive Care Medicine provider in New York, New York. Dr. Sulica is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Hypertension. Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Cerebral Hypoxia, and Acute Interstitial Pneumonia.

Distinguished in Pulmonary Hypertension
Dr. Ruth Minkin
Pulmonary Medicine | Intensive Care Medicine
Distinguished in Pulmonary Hypertension
Dr. Ruth Minkin
Pulmonary Medicine | Intensive Care Medicine

Kings Physician Services PC

506 6th St, 
Brooklyn, NY 
 (44.2 miles away)
718-780-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ruth Minkin is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Brooklyn, New York. Dr. Minkin is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Hypertension. Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Pulmonary Arteriovenous Fistula, and Lung Metastases.

Distinguished in Pulmonary Hypertension
Dr. Samuel Acquah
Intensive Care Medicine
Distinguished in Pulmonary Hypertension
Dr. Samuel Acquah
Intensive Care Medicine

Gramercy Park Physicians LLP

10 Union Sq E, 
New York, NY 
 (48.6 miles away)
212-420-2377
Languages Spoken:
English
See accepted insurances

Samuel Acquah is an Intensive Care Medicine provider in New York, New York. Dr. Acquah is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Hypertension. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Pneumonia, Embolectomy, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Migliore's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile